GlassScriptPhysician profile
Muhammad Alvi
NPI 1992227953
$4,967.59
in general payments reported to CMS, 2019-2025
18 companies · $4,685 in 2025
The $4,685 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $282 · 2025: $4,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,375 · Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,374.73 |
| Food and Beverage | $1,092.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,891.72 | 2025 | |
| United Therapeutics Corporation | $114.60 | 2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $109.13 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $105.22 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $100.98 | 2024-2025 | Breztri, Fasenra, Airsupra |
| Insmed, INC. | $92.93 | 2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $82.36 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $81.68 | 2024-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $77.89 | 2025 | |
| Ethicon INC. | $57.01 | 2024 | Monarch Platform |
| Pulmonx Corporation | $47.63 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.68 | 2024-2025 | Ofev |
| Grifols USA, LLC | $34.51 | 2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $33.35 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $29.57 | 2024 | Keytruda |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.68 | 2024 | Tezspire |
| Mylan Specialty L.P. | $21.38 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $21.27 | 2025 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Alvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.